Targeting the PI3K/AKT/ PTEN pathway in HR+/HER2- metastatic breast cancer
20 Nov 2025
byDr. Shaheenah Dawood, Head of the Oncology Clinical Trials Programme and Director of Oncology Services, Oncology Services at Mediclinic City Hospital, Dubai, United Arab Emirates
When treating hormone receptor–positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC), it is important to target the oestrogen receptor (ER) pathway for as long as the disease remains endocrine-sensitive. In an interview with MIMS Oncology, Dr Shaheenah Dawood, Head of the Oncology Clinical Trials Programme and Director of Oncology Services at Mediclinic City Hospital, Dubai, United Arab Emirates, described how co-targeting both the PI3K/AKT/mTOR and ER pathways with capivasertib and fulvestrant optimizes endocrine therapy (ET) to benefit patients with PIK3CA/AKT1/PTEN-altered HR+/HER2- mBC.
